Slides
Page 1
Third Quarter 2026 Financial Results & Business Update OCTOBER 29, 2026
Page 2
01 Introduction Alexis Smith | VP, Investor Relations 04 Financial Results Suky Upadhyay | EVP, Chief Financial Officer 06 Q&A Steven Stein, M.D. | EVP, Chief Medical Officer and Head of Late-Stage Development Dave Gardner | EVP, Chief Strategy Officer Mohamed Issa, Pharm.D. | EVP, Head of US Commercial02 Business Performance Bill Meury | Chief Executive Officer 05 Closing Remarks Bill Meury | Chief Executive Officer 03 R&D Highlights Pablo Cagnoni, M.D. | President, Global Head of R&D Agenda 2 © 2026 Incyte
Page 3
Forward looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding Incyte’s expected financial and operational performance; Incyte’s updated 2026 full year financial guidance; expectations regarding the impact of Incyte’s agreement with CMS; Incyte’s ability to deliver sustained long-term growth and create long-term value for patients and shareholders; the strength and growth of Incyte’s core business and marketed products; expectations regarding the future growth and potential size of Incyte’s core business, including the core business excluding Jakafi, and the potential contribution of Incyte’s pipeline to future revenue growth; the potential and progress of programs in Incyte’s pipeline, including their potential to provide significant future growth opportunities; expectations regarding the initiation, timing, progress, design, scope and results of clinical trials, proof-of-concept programs, combination studies and registrational development programs, and anticipated data readouts, including for Niktimvo (axatilimab), INCA033989 (mutCALR), INCA041798, INCA035784, latarcibart, INCB161734 (KRAS G12D), INCA33890 (TGFβR2×PD-1), INCB123667 (CDK2), Opzelura (ruxolitinib) cream and povorcitinib; expectations regarding regulatory submissions, regulatory decisions, approvals and commercial launches, including for Monjuvi in newly diagnosed DLBCL and povorcitinib in hidradenitis suppurativa and nonsegmental vitiligo; expectations regarding the Vega Therapeutics acquisition and the potential benefits of latarcibart; Incyte’s goals of building diversified growth pipelines in hematology, oncology, and inflammation and autoimmunity and establishing long-term leadership in myeloproliferative neoplasms and gastrointestinal oncology; expectations regarding Incyte’s partnerships and collaborations; and Incyte’s aspirations and goals. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; the efficacy or safety of Incyte’s products; Incyte’s ability to achieve commercial success for its marketed products and product candidates, if approved; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; greater than expected expenses, including expenses relating to litigation or strategic activities; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for Incyte’s products; the impact of agreements or arrangements with governmental authorities relating to the pricing, reimbursement or coverage of Incyte’s products; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. 3 © 2026 Incyte
Page 4
Opening Remarks & Business Progress Bill Meury | Chief Executive Officer
Page 5
© 2026 Incyte5 Strategy for the transition and recovery Core business The foundation Late-stage pipeline The next phase of growth Scale beyond Jakafi to navigate the 2029 transition and fund R&D Opportunity to build a significantly larger company over the next decade Layer on top of the core business to drive growth post the transition
Page 6
KRAS G12D inhibitor mutCALR antibody Protein S modulator JAK1 selective inhibitor TGFβR2×PD-1 bispecific CDK2 inhibitor ~74k patients with KRAS G12D–mutated disease across PDAC and CRC1,3-4 Pancreatic & colorectal cancer ~30k patients with CALR-mutated ET and MF2,5 Myeloproliferative neoplasms ~135k diagnosed VWD patients2,6 VWD and other bleeding disorders ~700k HS, PN and vitiligo patients2,7-9 HS, prurigo nodularis and vitiligo ~200k patients with metastatic MSS CRC1,10 Colorectal cancer ~10k patients with CCNE1+ ovarian cancer1,11 Ovarian cancer (CCNE1+) Potential first-in-class assets in late-stage development 1U.S., EU and Japan. 2 In the U.S. 3 DRG 2026. Lee J.K., et al. npj Precis. Onc. 2022;6(91) 4 Osterlund E, et al. J Clin Oncol, 2026;44, 3623. 5 Klampfl T, et al. N Engl J Med. 2013;369(25):2379-2390. 6Komodo Health claims database. 7Garg et al. JAMA Dermatol. 2017;153(8):760-764. 8Ständer S, et al. JAAD Int. 2020;2:28-30. 9Data on file. 10DRG 2025. Buchler T, Front. Oncol. 2022;12:888181. 11Clarivate/DRG Ovarian Cancer Disease Landscape and Forecast and published CCNE1 prevalence6 © 2026 Incyte INCB161734 INCA033989 LATARCIBART POVORCITINIB INCA33890 INCB123667
Page 7
Strong 3Q results and execution across the pipeline 7 1Reflects net sales, excluding royalty revenue and milestone and contract revenue. 2 Includes Monjuvi/Minjuvi for 1L DLBCL and povorcitinib for HS. Delivering on core business Core business (ex-Jakafi) $490M (+37% YoY)1 Regulatory and launch progress Advancing late-stage pipeline Approval and launch of Opzelura in mAD in Europe Phase 3 studies underway or planned for ’989 in 2L ET & 2L MF and latarcibart in VWD Expanding GI scope for ’734 and ’890 across settings and tumor types Total net sales $1.32B (+14% YoY)1 Two near-term potential approvals and launches (Monjuvi, povorcitinib)2 © 2026 Incyte
Page 8
$1.56B 3Q26 total revenue (+14% vs. 3Q25)1 • $1.32B total net sales • $241M royalty & contract revenue Total revenue reached $1.56B, increasing 14% versus prior year 1Reflects net sales, royalty revenue, and milestone and contract revenue. 8 © 2026 Incyte +14% Total net sales Total revenue Total Revenue1 $1.56B 3Q 2026 Total Revenue1 3Q26 3Q25 3Q24 3Q23 3Q22 $1.37B $1.14B $919M $823M
Page 9
$1.32B 3Q26 total net sales (+14% vs. 3Q25)1 Total net sales growth of 14% driven by strong performance across core business 9 © 2026 Incyte 1Reflects net sales, excluding royalty revenue and milestone and contract revenue. $1.15B $963M $783M $713M 3Q26 3Q25 3Q24 3Q23 3Q22 Jakafi® Core Business (ex-Jakafi) $1.32B 3Q 2026 Net Sales1Total Net Sales1 +14%
Page 10
$827M 3Q26 net sales (+4% vs. 3Q25)1 • $15M 3Q26 Jakafi XR net sales Demand +12% vs. 3Q25 Broad based growth across PV, MF and GVHD XR uptake reflects both new and existing patients Channel inventory within normal range Jakafi demand and early XR adoption support franchise growth 1Reflects Jakafi IR + Jakafi XR net sales, excluding royalty revenue and milestone and contract revenue. 10 © 2026 Incyte Total Net Sales U.S. Jakafi1 $827M 3Q 2026 Net Sales1 +4% $791M 3Q25 3Q26 $741M 3Q24 $620M 3Q22 $636M 3Q23
Page 11
$490M 3Q26 net sales (+37% vs. 3Q25)1 Core business (ex-Jakafi) now represents >35% of total net sales for the quarter Potential to reach $3–$4B by 2030 Core business (ex-Jakafi) continues to grow, increasing 37% YoY Products Opzelura® Niktimvo Monjuvi®/Minjuvi® Zynyz® Pemazyre® Iclusig® 1Reflects net sales, excluding royalty revenue and milestone and contract revenue. JAKAFI, OPZELURA, MONJUVI/MINJUVI, PEMAZYRE and ZYNYZ are our registered trademarks; NIKTIMVO and JAKAFI XR are our trademarks. 11 © 2026 Incyte $147M $222M $359M +37% $490M 3Q 2026 Net Sales1 $93M Total Net Sales (ex-Jakafi)1 3Q25 3Q263Q243Q22 3Q23
Page 12
$255M 3Q26 net sales (+36% vs. 3Q25)1 • U.S. net sales of $208M (+45% vs. 3Q25) • +24% TRx growth • Ex-U.S. net sales of $47M (+5% vs. 3Q25) Growth drivers: expanded sales force, specific NP/PA engagement, and improved access Strong demand across indications and geographies drives Opzelura momentum 1Reflects net sales, excluding royalty revenue and milestone and contract revenue.12 © 2026 Incyte $188M $139M $38M $92M $255M 3Q 2026 Net Sales1 Total Net Sales Opzelura1 3Q25 3Q263Q243Q22 3Q23 +36%
Page 13
$235M 3Q26 net sales (+38% vs. 3Q25)1 driven by: • Niktimvo net sales of $67M (+47%)2 • Zynyz net sales of $58M (+157%)2 • Monjuvi/Minjuvi net sales of $55M (+30%)2 Hematology and Oncology portfolio growing 38% versus prior year 1Reflects net sales, excluding royalty revenue and milestone and contract revenue. 2Reflects sales growth compared to the third quarter of 2025. 13 © 2026 Incyte Products Niktimvo Monjuvi/Minjuvi Zynyz Pemazyre Iclusig $171M $83M $55M $55M $235M 3Q 2026 Net Sales1 Total Net Sales Hematology and Oncology1 3Q25 3Q263Q243Q22 3Q23 +38%
Page 14
Research & Development Highlights Pablo Cagnoni, M.D. | President, Global Head of R&D
Page 15
Advancing a novel late-stage pipeline to drive long-term growth 15 © 2026 Incyte IAI Ruxolitinib cream JAK1/2 — mild HS Povorcitinib JAK1 — moderate-severe PN Oncology INCB161734 KRAS G12Di — 1L PDAC, adjuvant PDAC, 2L/3L CRC INCB123667 CDK2i — 1L maintenance ovarian INCA33890 TGFβR2×PD-1 — 1L MSS CRC Hematology Latarcibart Protein S modulator — VWD Axatilimab CSF-1R — 1L chronic GVHD (+steroids, +ruxolitinib) INCA033989 mutCALR mAb — 2L ET & 2L MF Ongoing and planned pivotal trials by 1H27 10+ Potential first-in- class assets 6 Pivotal and POC readouts by YE26 5
Page 16
Building a leading mutation-targeted CALR franchise 16 ’989 mutCALR mAb ’798 mutCALR mAb Essential Thrombocythemia Advancing first-in-class mutation- targeted therapy in ET • Ph. 3 EXCALIBUR-ET2 (2L ET) ongoing Myelofibrosis Expanding development across lines of therapy • Ph. 3 initiation (2L MF) – 4Q26 • Ph. 1 data in 1L MF (monotherapy & + rux) – 4Q26 CALR-mutated MPNs Advancing next generation mutCALR antibody • Preclinical data – 4Q26 • Ph. 1 initiation – 1H27 © 2026 Incyte
Page 17
© 2026 Incyte17 Key Ph. 3 trial features: • Population: Type 1 and non-Type 1 mutCALR positive MF patients previously treated with a JAK inhibitor • Dosing: 750mg IV Q2W (Type 1); 2500mg IV Q2W (non-type 1) • Comparator: Best available therapy (BAT) • Coprimary endpoints (Type 1): SVR35 and TSS50 at Week 36 • Key secondary endpoint (Type 1): Composite endpoint at Week 361, integrating measures of disease burden and hematologic improvement 1Overall response defined as meeting specific criteria of 4 endpoints including hemoglobin, platelet, blasts in peripheral blood and spleen volume parameters. 2Cabagnols X et al. Leukemia. 2015.3Harrison c, et al. NEJM 2012 4 Mesa RA, et al. Blood. 2005. ~70% of patients are Type 12 ~2/3 of people do not respond adequately to SOC3 ~10k people in the U.S. with CALR+ MF’989: Pivotal Phase 3 in 2L MF to initiate by EOY risk of transformation to AML4 20%
Page 18
Advancing diversified late-stage hematology pipeline 18 • ’989 (mutCALR mAb) • ’798 (next generation mutCALR mAb) • ’784 (CALR x CD3 bispecific) • ’954 (JAK2V617F) Myeloproliferative Neoplasms Axatilimab • Ph. 2 (+ ruxolitinib) data – 1Q27 • Ph. 3 (+ steroids) topline data – early-2028 Graft-versus-host disease Latarcibart in VWD • Ph. 1/2 OLE data – 4Q26 • Ph. 3 topline data – early-2029 Bleeding disorders Advancing targeted therapies through early- and late-stage development Improving outcomes through earlier and combination-based interventions Potential to transform treatment of VWD with a novel, non-factor replacement approach © 2026 Incyte
Page 19
'734: Expanding development across tumor types and treatment settings 19 © 2026 Incyte Heavily-pretreated CRC1L PDAC Activity with cetuximab suggests synergy with EGFR in late-line CRC + cetuximab • ORR: 36%; DCR: 100% • Median PFS: 7.2 months Antitumor activity and early durability in combination with 1L SOC + mFOLFIRINOX • ORR¹: 81%; DCR: 100% • 6-month landmark PFS: 90% + GemNabP • ORR¹: 58%; DCR: 96% • 6-month landmark PFS: 80% ¹Includes confirmed responses and responses pending confirmation. Phase 3 DAWN-303 topline data in 1L PDAC 2028 Phase 3 DAWN-302 initiation in 2L/3L CRC 1H 2027 Phase 3 adjuvant PDAC initiation 2027
Page 20
'734: Expansion across tumors and lines — — — CTx +/- Phase 3 in 2027 CTx (mFFX / GnP) +/- Phase 3 DAWN-303 ongoing + navlimetostat (PRMT5i)+ SNV1521 (PARP1i) + CTx + cetuximab (FOLFOX / FOLFIRI) + cetuximab 2L/3L Phase 3 DAWN-302 in 1H 2027 + SNV1521 (PARP1i) + CTx + petosemtamab (EGFR x LGR5 bsAb) ADJUVANT 1L 2L+ PDAC CRC NSCLC and other 12D-mutated tumors Monotherapy : Represents ongoing POC or Phase 3 programs. 20 © 2026 Incyte
Page 21
'890: Potential immunotherapy backbone in MSS CRC 21 © 2026 Incyte 1L metastatic MSS CRC Phase 3 NEXERA-303 topline data in 1L MSS CRC 2029 2H 2026 Initiated POC adjuvant study in ctDNA-positive disease following surgery Efficacy in key populations • Liver metastases ORR: 83% • Peritoneal metastases ORR: 62% • PD-L1 TAP >1% ORR: 81% Encouraging antitumor activity and early durability ’890 + FOLFOX + bevacizumab • ORR: 71% • DCR: 100% • 6-month landmark PFS: 81%
Page 22
'890: A novel immunotherapy backbone in CRC — — — — — — ADJUVANT 1L 2L+ Monotherapy ctDNA+ post adjuvant chemo + FOLFOX + bevacizumab MSS · Phase 3 NEXERA-303 Ovarian + CTx +/- bevacizumab HNSCC + EGFR Ab NSCLC + CTx + muzastotug (next-gen CTLA-4) + bevacizumab + ADC CRC : Represents ongoing POC or Phase 3 programs. 22 © 2026 Incyte
Page 23
Expanding solid tumor pipeline with focus in GI ’890 TGFβR2×PD-1 bispecific ’734 KRAS G12D inhibitor ’667 CDK2 inhibitor MSS colorectal cancer Large, underserved population with no approved IO options • Ph. 3 NEXERA-303 (1L MSS CRC) data – 2029 • Ph. 2 NEXERA-204 (adjuvant ctDNA+) ongoing KRAS G12D mutated cancers Targeting a large clinical need across KRAS G12D-driven GI cancers • Ph. 3 DAWN-303 (1L PDAC) data – 2028 • Ph. 3 DAWN-302 (2L/3L CRC) initiation – 1H 2027 • Ph. 3 trial initiation in adjuvant PDAC – 2027 Ovarian cancer (CCNE1+) Addresses genetically defined, high-risk ovarian cancer subset • Ph. 2 MAESTRA-1 trial in PROC ongoing • Ph. 3 MAESTRA-3 (1L maintenance OC) initiation – 4Q26 23 © 2026 Incyte
Page 24
IAI: Multiple near-term clinical & regulatory milestones 1Launch estimates assume regulatory approvals in Europe and U.S. in late-2026 and 1Q27, respectively. Ruxolitinib Cream JAK1/2 small molecule Povorcitinib JAK1 small molecule Hidradenitis Suppurativa Potential third indication to expand addressable market • Ph. 3 studies ongoing (TRuE-HS1; TRuE-HS2) • Ph. 3 topline data – 4Q26 Hidradenitis Suppurativa Anchor indication with large commercial opportunity • Positive CHMP opinion for moderate to severe HS in 3Q • Anticipated EU/US approval & launch – 4Q26/1Q271 Nonsegmental Vitiligo Broadens franchise→ expansion to moderate-severe • Positive Ph. 3 data (STOP- V1; STOP-V2) in 2Q • Planned regulatory submissions – 1H27 Prurigo Nodularis JAK dependent immuno-derm disease • Ph. 3 studies ongoing (STOP-PN1; STOP-PN2) • Ph. 3 topline data – 4Q26 24 © 2026 Incyte
Page 25
’734 ’989 Latarcibart Povorcitinib ’890 ’667 • Ph. 3 1L PDAC topline data – 2028 • Ph. 3 adjuvant PDAC and 2L/3L CRC study initiations – 2027 KRAS G12D inhibitor • Ph. 3 2L ET study ongoing • Ph. 3 2L MF study initiation – 4Q26 mutCALR antibody • Ph. 3 VWD topline data – early-2029 Protein S modulator • Ph. 3 PN topline data – 4Q26 • Anticipated PDUFA/launch (HS) – 1Q27 • Planned submissions (vitiligo) – 1H27 JAK1 selective inhibitor • Ph. 3 1L MSS CRC topline data – 2029 TGFβR2×PD-1 bispecific • Ph. 3 1L maintenance OC initiation – 4Q26 CDK2 inhibitor Late-stage pipeline positioned to deliver meaningful topline growth through 2030s 25 © 2026 Incyte
Page 26
Financial Results Suky Upadhyay | EVP, Chief Financial Officer
Page 27
Non-GAAP adjustments © 2026 Incyte27 • Management has chosen to present financial highlights for the quarter and year-to-date periods ended September 30, 2026, and 2025 on both a GAAP and Non-GAAP basis in the belief that this Non-GAAP information is useful for investors. • Management uses such information internally and externally for establishing budgets, operating goals and financial planning purposes. These metrics are also used to manage the Company’s business and monitor performance. The Company adjusts, where appropriate, for expenses in order to reflect the Company’s core operations. • The Company believes these adjustments are useful to investors by providing an enhanced understanding of the financial performance of the Company’s core operations. The metrics have been adopted to align the Company with disclosures provided by industry peers. • As changes in exchange rates are an important factor in understanding period-to-period comparisons, Management believes the presentation of certain revenue results on a constant currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period over period. The Company calculates constant currency by calculating current year results using prior year foreign currency exchange rates and generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as the Company presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.
Page 28
Financial highlights – revenues © 2026 Incyte28 NA, not applicable. For all periods there were no adjustments between GAAP and Non-GAAP revenues. Totals may not add due to rounding. 1Includes $246 million impact from agreement with CMS during the second quarter of 2026 in relation to line extension. 2Pemazyre in the U.S., Canada, Europe, Japan, Asia Pacific (APAC), Middle East and Africa (MEA) and Latin America (LatAm); Niktimvo and Monjuvi in the U.S.; Zynyz in the U.S. and Europe; Iclusig in Europe and MEA; and Minjuvi in Canada, Europe, APAC, MEA and LatAm. $ MILLIONS Q3 2026 Q3 2025 YOY CHANGE YTD 2026 YTD 2025 YOY CHANGE GAAP GAAP AS REPORTED CONSTANT CURRENCY GAAP GAAP AS REPORTED CONSTANT CURRENCY Net sales 1,316 1,150 14% 15% 3,909 3,132 25% 25% Jakafi 827 791 4% NA 2,401 2,264 6% NA Opzelura1 255 188 36% 36% 848 471 80% 79% Hematology and Oncology2 235 171 38% 38% 661 396 67% 65% Royalties 191 171 12% 517 453 14% Jakavi 132 126 5% 6% 362 328 11% 7% Olumiant 39 37 5% 8% 114 101 12% 12% Tabrecta 7 7 5% NA 20 20 (0.3)% NA Other 13 2 582% NA 21 4 382% NA Total product & royalty revenues 1,507 1,321 14% 4,426 3,584 23% Milestone and contract revenue 50 45 11% 78 50 56% Total revenues 1,557 1,366 14% 4,504 3,634 24%
Page 29
Financial highlights – costs, expenses and other © 2026 Incyte29 NM, not meaningful. Totals may not add due to rounding. 1Includes $1,237.3 million and $1,249.9 million of upfront and milestone payments, inclusive of the Vega acquisition, for the three and nine months ended September 30, 2026, respectively, and $0.1 million and $28.2 million of upfront and milestone payments for the three and nine months ended September 30, 2025, respectively. Includes $2.6 million of Vega transition costs representing employee related costs to transition research and development activities and Vega acquisition related compensation expense related to retention payments, for both the three and nine months ended September 30, 2026. Includes $2.1 million of Escient acquisition related compensation expense related to severance payments for the nine months ended September 30, 2025. 2Excluding the Vega related IPR&D expense, R&D and total operating expenses for the third quarter of 2026 grew 11% and 12%, respectively, compared to prior year period. $ MILLIONS Q3 2026 Q3 2025 YOY CHANGE YTD 2026 YTD 2025 YOY CHANGE GAAP GAAP GAAP GAAP COGS 109 99 10% 318 251 27% As a percentage of net sales 8.3% 8.6% 8.1% 8.0% Contract dispute settlement — — NM — (242) NM R&D 1,792 507 254%2 2,825 1,439 96% R&D – ongoing 552 506 9% 1,573 1,408 12% R&D – upfront and milestones & acquisition-related costs1 1,240 0.1 NM 1,252 30 4,038% SG&A 364 329 11% 1,044 986 6% Asset impairment and related disposal costs — — NM 23 — NM Loss on change in fair value of acquisition - related contingent consideration 1 (12) NM 3 22 (85)% Total costs, expenses and other 2,266 922 146%2 4,213 2,455 72%
Page 30
CURRENT PREVIOUS Total net sales $5,210M - $5,300M $5,130M - $5,260M Jakafi1 Unchanged $3,220M - $3,270M Opzelura2 $1,100M - $1,120M $1,050M - $1,100M Hematology and Oncology3 $890M - $910M $860M - $890M Total R&D and SG&A operating expenses (GAAP)4 Unchanged $4,915M - $4,995M Total R&D and SG&A operating expenses (non-GAAP)4,5 Unchanged $4,625M - $4,695M Full year 2026 financial guidance © 2026 Incyte30 1Includes Jakafi IR & Jakafi XR net sales. 2 Includes net sales for moderate atopic dermatitis in Europe. 3Includes Pemazyre in the U.S., Canada, Europe, Japan, APAC, MEA, and LatAm; Niktimvo and Monjuvi in the U.S.; Zynyz in the U.S., Europe and Japan; Iclusig in Europe and MEA; and Minjuvi in Canada, Europe, Japan, APAC, MEA and LatAm. 4Includes upfront cost related to the acquisition of Vega Therapeutics which will be recognized as IPR&D expense impacting both the third quarter and full-year 2026 in addition to incremental R&D investment related to latarcibart. 5Adjusted to exclude the estimated cost of stock-based compensation.
Page 31
Q&A
Page 32
Thankyou
Page 33
Appendix
Page 34
THERAPEUTIC PROGRAM INDICATION(S) PROOF OF CONCEPT PIVOTAL MILESTONE/STATUS Hematology Axatilimab CSF-1R 1L cGvHD (+ ruxolitinib) Ph. 2 data 1Q27 1L cGvHD (+ steroids) Ph. 3 data early-2028 INCA033989 mutCALR CALR-mutated ET (2L) Ph. 3 trial ongoing CALR-mutated MF (1L) Ph. 1 data 4Q26 CALR-mutated MF (2L) Ph. 3 initiation 4Q26 INCA035784 CALRxCD3 bispecific CALR-mutated MF, ET Ph. 1 data 2027 Tafasitamab CD19 DLBCL (1L) Approval/launch 1Q27 Latarcibart Protein S modulator VWD Ph. 3 data early-2029 Oncology INCB123667 CDK2 PROC Ph. 2 trial ongoing Ovarian (1L maintenance) Ph. 3 initiation 4Q26 INCB161734 KRAS G12D PDAC (1L) Ph. 3 data 2028 INCA33890 TGFβR2×PD-1 bispecific MSS CRC (1L) Ph. 3 data 2029 IAI Ruxolitinib Cream JAK1/JAK2 HS (mild/moderate) Ph. 3 data 4Q26 Povorcitinib JAK1 HS (moderate/severe) Approval/launch late-2026 and 1Q271 PN (moderate/severe) Ph. 3 data 4Q26 Vitiligo (moderate/severe) sNDA submission 1H27 Asthma Ph. 2 data 4Q26 Upcoming pipeline milestones © 2026 Incyte34 1Anticipated approval and launch in the EU and US, respectively.
Page 35
Abbreviation directory © 2026 Incyte35 ’667 INCB123667 ET Essential thrombocythemia MPN Myeloproliferative neoplasms ’734 INCB161734 FDA U.S. Food and Drug Administration MSS Microsatellite stable ’890 INCA33890 FOLFIRI Folinic acid (leucovorin), fluorouracil and irinotecan OC Ovarian cancer ’989 INCA033989 FOLFOX Leucovorin, fluorouracil and oxaliplatin OLE Open label extension 1L First-line GI Gastrointestinal ORR Objective response rate 2L Second-line GnP Gemcitabine, nab-paclitaxel PDAC Pancreatic ductal adenocarcinoma AML Acute myeloid leukemia GVHD Graft-versus-host disease PFS Progression-free survival bev bevacizumab HS Hidradenitis suppurativa PN Prurigo nodularis bsAb Bispecific antibody IAI Inflammation & Autoimmunity POC Proof of concept ctDNA+ Circulating tumor DNA positve IO Immuno-oncology PROC Platinum-resistant ovarian cancer CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 IV Intravenous PV Polycythemia vera CTx Chemotherapy JAK Janus kinase Q2W Every two weeks CHMP Committee for Medicinal Products for Human Use KRAS Kirsten rat sarcoma SVR35 spleen volume reduction of 35% or greater from baseline CCNE+ Cyclin E1 positive LGR5 Leucine-rich repeat-containing G-protein coupled receptor 5 TRx Total prescription CRC Colorectal cancer mAb Monoclonal antibody TSS50 a ≥50% reduction in Total Symptom Score DCR Disease control rate mAD Moderate atopic dermatitis VWD Von Willebrand disease EGFR Epidermal growth factor receptor MF Myelofibrosis YoY Year-over-year ESMO European Society for Medical Oncology mFFX Modified leucovorin calcium, fluorouracil, irinotecan hydrochloride, oxaliplatin XR Extended-release